Roche’s Genentech unit has entered into a collaboration with Canada's Xenon Pharmaceuticals to discover compounds and diagnostics for treatment of pain.
Under the terms of the agreement, Genentech (which has an exclusive license to compounds and a non-exclusive right to any diagnostics) will pay an undisclosed upfront fee plus research funding. Xenon, which is privately owned and based in Vancouver, is eligible to receive R&D and commercialisation milestone payments, totalling up to $646 million, plus royalties.
Michael Hayden, chief scientific officer at Xenon, said the alliance, "which represents our sixth partnership with a major pharmaceutical company to date, once again highlights the keen interest in Xenon’s unique genetics approach and in our translational R&D capabilities".
Xenon's other partners include Takeda, Novartis and Merck & Co.
The views expressed in the following comments are not those of PharmaTimes or any connected third party and belong specifically to the individual who made that comment. We accept no liability for the comments made and always advise users to exercise caution.